Free Trial
NYSE:PRGO

Perrigo (PRGO) Stock Price, News & Analysis

$27.88
-0.24 (-0.85%)
(As of 05/24/2024 07:00 PM ET)
Today's Range
$27.60
$28.34
50-Day Range
$27.88
$33.43
52-Week Range
$25.77
$40.28
Volume
1.81 million shs
Average Volume
1.77 million shs
Market Capitalization
$3.80 billion
P/E Ratio
N/A
Dividend Yield
3.95%
Price Target
$40.67

Perrigo MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
45.9% Upside
$40.67 Price Target
Short Interest
Healthy
2.54% of Shares Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-1.93
Upright™ Environmental Score
News Sentiment
1.34mentions of Perrigo in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$475,227 Bought Last Quarter
Proj. Earnings Growth
25.68%
From $2.57 to $3.23 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

5.00 out of 5 stars

Medical Sector

1st out of 921 stocks

Pharmaceutical Preparations Industry

1st out of 431 stocks

PRGO stock logo

About Perrigo Stock (NYSE:PRGO)

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

PRGO Stock Price History

PRGO Stock News Headlines

Perrigo Sees Unusually High Options Volume (NYSE:PRGO)
Perrigo Q1 Earnings Surpass, Sales Miss Estimates
Perrigo Company plc Q1 Earnings Summary
Perrigo Reaffirms 2024 Outlook - Update
Perrigo Announces Quarterly Dividend
See More Headlines
Receive PRGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Perrigo and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 3/26 Dividend
3/07/2024
Dividend Payable
3/26/2024
Last Earnings
5/04/2024
Today
5/27/2024
Ex-Dividend for 6/18 Dividend
5/31/2024
Dividend Payable
6/18/2024
Next Earnings (Estimated)
8/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
CUSIP
71429010
Employees
9,140
Year Founded
1887

Price Target and Rating

Average Stock Price Target
$40.67
High Stock Price Target
$42.00
Low Stock Price Target
$39.00
Potential Upside/Downside
+45.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-12,700,000.00
Pretax Margin
-2.44%

Debt

Sales & Book Value

Annual Sales
$4.66 billion
Cash Flow
$5.27 per share
Book Value
$35.19 per share

Miscellaneous

Free Float
135,775,000
Market Cap
$3.80 billion
Optionable
Optionable
Beta
0.63

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

PRGO Stock Analysis - Frequently Asked Questions

Should I buy or sell Perrigo stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Perrigo in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PRGO shares.
View PRGO analyst ratings
or view top-rated stocks.

What is Perrigo's stock price target for 2024?

3 analysts have issued 1 year target prices for Perrigo's shares. Their PRGO share price targets range from $39.00 to $42.00. On average, they expect the company's stock price to reach $40.67 in the next twelve months. This suggests a possible upside of 45.9% from the stock's current price.
View analysts price targets for PRGO
or view top-rated stocks among Wall Street analysts.

How have PRGO shares performed in 2024?

Perrigo's stock was trading at $32.18 at the beginning of 2024. Since then, PRGO stock has decreased by 13.4% and is now trading at $27.88.
View the best growth stocks for 2024 here
.

When is Perrigo's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our PRGO earnings forecast
.

How were Perrigo's earnings last quarter?

Perrigo Company plc (NYSE:PRGO) issued its earnings results on Saturday, May, 4th. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.06. The company earned $1.08 billion during the quarter, compared to the consensus estimate of $1.09 billion. Perrigo had a positive trailing twelve-month return on equity of 6.96% and a negative net margin of 0.17%. Perrigo's quarterly revenue was down 8.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.45 EPS.
Read the conference call transcript
.

How often does Perrigo pay dividends? What is the dividend yield for Perrigo?

Perrigo declared a quarterly dividend on Wednesday, May 1st. Shareholders of record on Friday, May 31st will be paid a dividend of $0.276 per share on Tuesday, June 18th. This represents a $1.10 dividend on an annualized basis and a yield of 3.96%. The ex-dividend date is Friday, May 31st.
Read our dividend analysis for PRGO
.

Is Perrigo a good dividend stock?

Perrigo (NYSE:PRGO) pays an annual dividend of $1.10 per share and currently has a dividend yield of 3.96%. PRGO has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer.
Read our dividend analysis for PRGO.

What guidance has Perrigo issued on next quarter's earnings?

Perrigo issued an update on its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share guidance of 2.500-2.650 for the period, compared to the consensus EPS estimate of 2.350. The company issued revenue guidance of $4.7 billion-$4.7 billion, compared to the consensus revenue estimate of $4.7 billion.

What is Murray S. Kessler's approval rating as Perrigo's CEO?

38 employees have rated Perrigo Chief Executive Officer Murray S. Kessler on Glassdoor.com. Murray S. Kessler has an approval rating of 83% among the company's employees.

What other stocks do shareholders of Perrigo own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Perrigo investors own include Teva Pharmaceutical Industries (TEVA), Gilead Sciences (GILD), Mylan (MYL), AbbVie (ABBV), Allergan (AGN), Intel (INTC), Johnson & Johnson (JNJ), Netflix (NFLX), QUALCOMM (QCOM) and Amgen (AMGN).

Who are Perrigo's major shareholders?

Perrigo's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (11.01%), DAVENPORT & Co LLC (2.55%), Perpetual Ltd (2.05%), Heartland Advisors Inc. (0.91%), Bahl & Gaynor Inc. (0.67%) and ProShare Advisors LLC (0.67%). Insiders that own company stock include Alison Ives, Bradley A Alford, Eduardo Guarita Bezerra, Geoffrey M Parker, Grainne Quinn, James E Dillard III, Murray S Kessler, Patrick Lockwood-Taylor, Raymond Silcock, Robert Willis, Rolf A Classon, Ronald Craig Janish, Svend Andersen, Thomas Farrington and Todd W Kingma.
View institutional ownership trends
.

How do I buy shares of Perrigo?

Shares of PRGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Perrigo have any subsidiaries?
The following companies are subsidiares of Perrigo: 010414 UK Limited, 251211 UK Limited, Abtei Omega Pharma GmbH, Aco Hud Nordic AB, Adriatic BST Trgovina in Storitve D.o.o., Adriatic Distribution doo Beograd, Agis Industries, Algorithmics Risk Management Limited, Arginet Investments and Property (2003) Ltd., Athena Neurosciences LLC, Aurora Pharmaceuticals Pty Ltd, Biover NV, Blue Wolf Global Limited, Bluewolf International Limited, Brunel Healthcare Manufacturing Limited, CP Kayak Holdings Inc., CanNegev Ltd, Chefaro Ireland Designated Activity Company, Cinetic Laboratories Argentina SA, Cleversafe UK Limited, Cosmediet - Biotechnie SAS, Despharma Kft., Elan Corporation, Elan Europa Finance S.á r.l., Elan International Services Limited, Elan Pharmaceuticals LLC, Fera Pharmaceuticals, Galpharm Healthcare Limited, Galpharm International, Galpharm International Limited, Geiss Destin & Dunn, Gelcaps Exportadora de Mexico S.A. de C.V., Gr8ness LLC, HRA Pharma, Habsont Unlimited Company, Heartbeat Experts Limited, IBM GF international Treasury Company, IBM International Treasury Services Unlimited Company, IBM Netherlands Treasury B.V., Interdelta S.A., International Business Machines Limited, Irish Biosciences Venture Capital Fund, JB Laboratories, JLR Pharma S.A., Jaico R.D.P. NV, Jewel Consumer Care Pvt. Ltd., Kazmira LLC, Kenexa Global Recruitment Services Limited, Kenexa Quorum Holdings Limited, Kenexa Technology LLC, Kiteacre Limited, L. Perrigo Company, Laboratoire de la Mer SAS, Laboratoires Omega Pharma France SAS, Laboratorios DIBA S.A., Laboratorios Diba, Luxembourg Investment Company 289 Sàrl, MH (UK) Limited, Medgenix Benelux NV, Monksland Holdings B.V., Naturwohl Pharma GmbH, ORION Laboratories, Oce Bio BV, Oce-Bio Nederland B.V., Omega Alpharm Cyprus Ltd., Omega Pharma, Omega Pharma AS, Omega Pharma Australia Pty Ltd, Omega Pharma Austria Healthcare GmbH, Omega Pharma Baltics SIA, Omega Pharma Belgium NV, Omega Pharma Capital NV, Omega Pharma Deutschland GmbH, Omega Pharma GmbH, Omega Pharma Hellas SA Health and Beauty Products, Omega Pharma Hungary Kft., Omega Pharma Innovation & Development NV, Omega Pharma International NV, Omega Pharma Limited, Omega Pharma Luxembourg SarL, Omega Pharma Manufacturing GmbH & Co. KG, Omega Pharma Manufacturing Verwaltungs GmbH, Omega Pharma Nederland B.V., Omega Pharma Trading NV, Omega Pharma s.r.o., Omega Teknika Designated Activity Company, OmegaLabs (Pty) Ltd, Oniqua Europe Limited, Optevia Limited, Orion Laboratories (NZ) Ltd., Orion Laboratories PTY Limited, P-Direct NL B.V., P2C Inc., PBM Canada Holdings LLC, PBM China Holdings LLC, PBM Foods LLC, PBM Holdings LLC, PBM International Holdings LLC, PBM Mexico Holdings LLC, PBM Nutritionals LLC, PBM Products, PBM Products LLC, PBM Products Mexico S de R.L. de C.V., PMI Branded Pharmaceuticals Inc., Paddock Laboratories, Paracelsia Pharma GmbH, Perrigo Asia Holding Company Ltd., Perrigo Australian Holding Company II PTY Limited, Perrigo Bulgaria OOD, Perrigo China Business Trust, Perrigo China Business Trustee LLC, Perrigo Company, Perrigo Company Charitable Foundation, Perrigo Company of Tennessee, Perrigo Company plc, Perrigo Corporation Designated Activity Company, Perrigo Danmark A/S, Perrigo Diabetes Care LLC, Perrigo Direct Inc., Perrigo España SA, Perrigo Europe Invest NV, Perrigo Finance (US) LLC, Perrigo Finance Unlimited Company, Perrigo Florida Inc., Perrigo France SAS, Perrigo Global Holdings Inc., Perrigo Holding NV, Perrigo Holdings Unlimited Company, Perrigo International Finance Designated Activity Company, Perrigo International Holdings II Inc., Perrigo International Holdings LLC, Perrigo International Inc., Perrigo International Insurance Limited, Perrigo Ireland 1 Designated Activity Company, Perrigo Ireland 10 Unlimited Company, Perrigo Ireland 11 DAC, Perrigo Ireland 12 Designated Activity Company, Perrigo Ireland 13 Designated Activity Company, Perrigo Ireland 2 Designated Activity Company, Perrigo Ireland 3 Designated Activity Company, Perrigo Ireland 4 Unlimited Company, Perrigo Ireland 5 Unlimited Company, Perrigo Ireland 6 Unlimited Company, Perrigo Ireland 7 Designated Activity Company, Perrigo Ireland 8 Designated Activity Company, Perrigo Ireland 9 Unlimited Company, Perrigo Ireland Holding Company B.V., Perrigo Ireland Management Designated Activity Company, Perrigo Israel Enterprises & Investments Ltd., Perrigo Israel Holdings II B.V., Perrigo Israel Opportunities II Ltd., Perrigo Israel Trading Limited Partnership, Perrigo Italia S.r.l, Perrigo Kişisel Bakım Ürünleri Sanayi ve Ticaret Limited Şirketi, Perrigo LLC, Perrigo Laboratories India Private Limited, Perrigo Management Company, Perrigo Mexico Holding S.A. de C.V., Perrigo Mexico Investment Holdings LLC, Perrigo Netherlands B.V., Perrigo Netherlands Finco 1 Coöperatief U.A., Perrigo Netherlands Finco 2 B.V., Perrigo Netherlands International Partnership C.V., Perrigo New York Inc., Perrigo Norge AS, Perrigo Oral Health Care Holdings Inc., Perrigo Pharma Holding Nederland BV, Perrigo Pharma International Designated Activity Company, Perrigo Pharma Limited, Perrigo Poland Sp.z.o.o, Perrigo Portugal LDA, Perrigo Research & Development Company, Perrigo România S.R.L., Perrigo Sales Corporation, Perrigo Science Eight Unlimited Company, Perrigo Science One Designated Activity Company, Perrigo Suomi Oy, Perrigo Sverige AB, Perrigo Trading (Shanghai) Co. Ltd., Perrigo UK Acquisition Limited, Perrigo UK Finco Limited Partnership, Perrigo Ukraine LLC, Perrigo Ventures Limited Partnership, Perrigo de Mexico S.A. de C.V., Perrigo do Brasil Farmaceutica Ltda., Pharma Clal (1983) Ltd., Promontory Financial Group (UK) Limited, Quimica y Farmacia S.A. de C.V., Ranir, Ranir (Holdings) Limited, Ranir Changshu Oral Care CO. Ltd., Ranir Global Holdings LLC, Ranir LLC, Ranir Limited, Resilient Systems Europe Limited, Richard Bittner AG, Rosemont Pharmaceuticals, Rubicon Healthcare Holdings Pty Ltd, SPSS Limited, Samenwerkende Apothekers Nederland B.V., ScarAway, Silverpop Systems Limited, Simpler Consulting Limited, Solent Dental Company Limited, Solent Oral Care Limited, Sterling Commerce (UK) Limited, The Analytic Sciences Corporation Limited, The Learning Pharmacy Limited, The Weather Channel Global Media Limited, Totalcare International Corp, Transitive Corporation Limited, Transitive Limited, Truven Health Analytics UK Limited, Velcera, Weather Services International Limited, Wrafton Laboratories, Wrafton Laboratories Limited, Zibo Xinhua - Perrigo Pharmaceutical Company Ltd., i2 Holdings Limited, i2 Intermediate Holdings Limited, and i2 Limited.
Read More
This page (NYSE:PRGO) was last updated on 5/27/2024 by MarketBeat.com Staff

From Our Partners